AstraZeneca PLC AZN
At closeNov 3, 2026, 4:52 PM EST
After hours · Nov 3, 4:52 PM ET
- YTD
- +0.01%
- 1 year
- +12.51%
- Market cap
- 285.18B
- Revenue (ttm)
- 62.38B
- Profit margin
- 17.68%
- EPS (ttm)
- 7.07
- Shares out
- 1.55B
- P/E ratio
- 26.01
- Forward P/E
- 16.25
- Dividend
- 3.20 (1.72%)
- Ex-dividend date
- Aug 6, 2026
- YTD return
- +0.01%
- 1-year return
- +12.51%
- Volume
- 3.68M
- Avg volume
- 3.26M
- Open
- 186.11
- Previous close
- 186.58
- Day's range
- 182.95 – 187.35
- 52-week range
- 153.41 – 212.71
- Beta
- 0.17
- Analysts
- Buy
- Price target
- 206.66 (+12.4%)
- Earnings date
- Feb 9, 2027
30m +13.00 (+7.61%)
Key statistics
- Enterprise value
- 315.63B
- PEG ratio
- 1.32
- Price / sales
- 4.57
- Price / book
- 5.51
- Dividend yield
- 1.72%
- Payout ratio
- 45.38%
- Revenue growth
- 6.70%
- Free cash flow
- 5.63B
- Total cash
- 8.17B
- Total debt
- 34.33B
- Return on equity
- 22.57%
- Short % of float
- 0.21%
- 50-day average
- 164.89
- 200-day average
- 180.15
Analyst view
Consensus: buy
- Target (low)
- 158.00
- Target (mean)
- 206.66
- Target (high)
- 240.00
- Strong buy2
- Buy7
- Hold2
- Sell1
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 2.34 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 2.60 | 2.79 | +0.19 | +7.31% |
| Jul 27, 2026 | Jun 30, 2026 | 2.50 | 2.63 | +0.13 | +5.20% |
| Apr 29, 2026 | Mar 31, 2026 | 2.57 | 2.58 | +0.01 | +0.39% |
| Feb 10, 2026 | Dec 31, 2025 | 2.09 | 2.12 | +0.03 | +1.44% |
| Nov 6, 2025 | Sep 30, 2025 | 2.28 | 2.38 | +0.10 | +4.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | CICC | init | — | Outperform |
| Feb 13, 2025 | UBS | up | Neutral | Buy |
| Nov 20, 2024 | UBS | up | Sell | Neutral |
| Sep 11, 2024 | Erste Group | up | Hold | Buy |
| Aug 12, 2024 | TD Cowen | main | Buy | Buy |
| May 30, 2024 | Argus Research | main | Buy | Buy |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United Kingdom
- Website
- astrazeneca.com
News
AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing 
Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter 
27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC 
1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich 
AstraZeneca: 3 Key Takeaways for Long-Term Investors 
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell? 
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC 
AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell? 
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript 
AstraZeneca Q3 Earnings Call Highlights
Your note
Sign in to keep a note on AZN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BlackRock Financial Management, Inc. | — | Annual Return | Jan 30, 2026 | 100,885,181 |
| Broadley (Philip) | — | Annual Return | Dec 30, 2025 | 8,025 |
| Demare (Michel) | — | Bought | Sep 13, 2026 | 12,500 |
| Investor AB | — | Annual Return | Jan 30, 2026 | 51,587,810 |
| McCoy (Sherilyn S) | — | Annual Return | Dec 30, 2025 | 1,736 |
| Mok (Tony Shu Kam) | — | Annual Return | Dec 30, 2025 | 3,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Investor AB | 3.33% | 51,587,810 | 9.49B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.93% | 45,386,190 | 8.35B | Jun 29, 2026 |
| Capital International Investors | 2.23% | 34,576,070 | 6.36B | Jun 29, 2026 |
| NORGES BANK | 2.18% | 33,864,172 | 6.23B | Jun 29, 2026 |
| Capital World Investors | 1.94% | 30,075,134 | 5.53B | Jun 29, 2026 |
| FMR, LLC | 1.86% | 28,895,264 | 5.31B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.42% | 22,045,658 | 4.05B | Jul 30, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.95% | 14,666,227 | 2.70B | Jun 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 0.77% | 11,923,074 | 2.19B | Jun 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.74% | 11,467,645 | 2.11B | Sep 29, 2026 |
| NEW PERSPECTIVE FUND | 0.73% | 11,260,404 | 2.07B | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 0.66% | 10,300,505 | 1.89B | Jul 30, 2026 |